

Anthony Culyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6652753/publications.pdf>

Version: 2024-02-01

48
papers

1,743
citations

394421

19
h-index

289244

40
g-index

50
all docs

50
docs citations

50
times ranked

2101
citing authors

#	ARTICLE	IF	CITATIONS
1	Welfarism vs. extra-welfarism. <i>Journal of Health Economics</i> , 2008, 27, 325-338.	2.7	260
2	The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. <i>Value in Health</i> , 2016, 19, 921-928.	0.3	203
3	Using Cost-Effectiveness Analysis to Address Health Equity Concerns. <i>Value in Health</i> , 2017, 20, 206-212.	0.3	181
4	Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. <i>Journal of Health Services Research and Policy</i> , 2007, 12, 56-58.	1.7	155
5	Priority-setting for achieving universal health coverage. <i>Bulletin of the World Health Organization</i> , 2016, 94, 462-467.	3.3	108
6	Deliberative processes and evidence-informed decision making in healthcare: do they work and how might we know?. <i>Evidence and Policy</i> , 2006, 2, 357-371.	1.0	98
7	CAUSES FOR CONCERN: IS NICE FAILING TO UPHOLD ITS RESPONSIBILITIES TO ALL NHS PATIENTS?. <i>Health Economics (United Kingdom)</i> , 2015, 24, 1-7.	1.7	88
8	Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use. <i>Health Economics, Policy and Law</i> , 2016, 11, 415-432.	1.8	76
9	An Equity Framework for Health Technology Assessments. <i>Medical Decision Making</i> , 2012, 32, 428-441.	2.4	46
10	Distributional Cost-Effectiveness Analysis Comes of Age. <i>Value in Health</i> , 2021, 24, 118-120.	0.3	44
11	NICE's use of cost effectiveness as an exemplar of a deliberative process. <i>Health Economics, Policy and Law</i> , 2006, 1, 299-318.	1.8	39
12	Involving Stakeholders in Healthcare Decisions - The Experience of the National Institute for Health and Clinical Excellence (NICE) in England and Wales. <i>Healthcare Quarterly</i> , 2005, 8, 56-60.	0.7	38
13	What next after GDP-based cost-effectiveness thresholds?. <i>Gates Open Research</i> , 2020, 4, 176.	1.1	36
14	Evidence-informed capacity building for setting health priorities in low- and middle-income countries: A framework and recommendations for further research. <i>F1000Research</i> , 2017, 6, 231.	1.6	35
15	How can we evaluate the cost-effectiveness of health system strengthening? A typology and illustrations. <i>Social Science and Medicine</i> , 2019, 220, 141-149.	3.8	30
16	FROM TALK TO ACTION: POLICY STAKEHOLDERS, APPROPRIATENESS, AND SELECTIVE DISINVESTMENT. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 236-240.	0.5	28
17	Health Technology Assessment: Global Advocacy and Local Realities Comment on "Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness". <i>International Journal of Health Policy and Management</i> , 2017, 6, 233-236.	0.9	28
18	Prevention of non-communicable disease: best buys, wasted buys, and contestable buys. <i>BMJ, The</i> , 2020, 368, m141.	6.0	25

#	ARTICLE	IF	CITATIONS
19	Economic Evaluation for Health Investments En Route to Universal Health Coverage: Cost-Benefit Analysis or Cost-Effectiveness Analysis?. <i>Value in Health</i> , 2019, 22, 99-103.	0.3	20
20	National Institute for Health and Care Excellence, social values and healthcare priority setting. <i>Journal of the Royal Society of Medicine</i> , 2019, 112, 173-179.	2.0	19
21	Does MCDA Trump CEA?. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 147-151.	2.1	17
22	Equity of What in Healthcare? Why the Traditional Answers Don't Help Policy - and What to Do in the Future. <i>HealthcarePapers</i> , 2007, 8, 12-26.	0.3	14
23	Avoiding health technology assessment: a global survey of reasons for not using health technology assessment in decision making. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 62.	1.5	14
24	Rival perspectives in health technology assessment and other economic evaluations for investing in global and national health. Who decides? Who pays?. <i>F1000Research</i> , 2018, 7, 72.	1.6	13
25	Perspective and Desire in Comparative Effectiveness Research. <i>Pharmacoeconomics</i> , 2010, 28, 889-897.	3.3	11
26	Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa. <i>Value in Health Regional Issues</i> , 2019, 19, 65-74.	1.2	11
27	A Systematic Review of Demand-Side Methods of Estimating the Societal Monetary Value of Health Gain. <i>Value in Health</i> , 2021, 24, 1423-1434.	0.3	11
28	Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force. <i>Value in Health</i> , 2022, 25, 869-886.	0.3	11
29	National Health Insurance in South Africa: Relevance of a national priority-setting agency. <i>South African Medical Journal</i> , 2015, 105, 739.	0.6	10
30	A Health Economics Approach to US Value Frameworks: Serving the Needs of Decision Making. <i>Value in Health</i> , 2018, 21, 117-118.	0.3	10
31	HTA â€“ Algorithm or Process? Comment on "Expanded HTA: Enhancing Fairness and Legitimacy". <i>International Journal of Health Policy and Management</i> , 2016, 5, 501-505.	0.9	10
32	Hic Sunt Dracones. <i>Medical Decision Making</i> , 2012, 32, E25-E32.	2.4	8
33	Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, .	0.5	8
34	Building Capacity for Evidence-Informed Priority Setting in the Indian Health System: An International Collaborative Experience. <i>Health Policy OPEN</i> , 2020, 1, 100004.	1.5	7
35	Use of Evidence-Informed Deliberative Processes â€“ Learning by Doing Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe". <i>International Journal of Health Policy and Management</i> , 2020, 9, 263-265.	0.9	6
36	Disability and multidimensional quality of life: A capability approach to health status assessment. <i>Health Economics (United Kingdom)</i> , 2020, 29, 748-765.	1.7	5

#	ARTICLE	IF	CITATIONS
37	How can we make better health decisions: a Best Buy for all?. Gates Open Research, 2019, 3, 1543.	1.1	5
38	Charging for the use of survey instruments on population health: the case of quality-adjusted life years. Bulletin of the World Health Organization, 2020, 98, 59-65.	3.3	3
39	Making Choices on the Journey to Universal Health Care Coverage: From Advocacy to Analysis. Value in Health, 2016, 19, 910-912.	0.3	2
40	How can we make better health decisions a Best Buy for all?. Gates Open Research, 0, 3, 1543.	1.1	2
41	How concentrated are academic publications of countries' progression towards universal health coverage?. The Lancet Global Health, 2019, 7, e696-e697.	6.3	1
42	9. Deliberative Processes in Decisions about Best Buys, Wasted Buys, and Contestable Buys. , 2019, , 147-170.		1
43	We need a NICE for global development spending. F1000Research, 2017, 6, 1223.	1.6	1
44	Cost-effectiveness thresholds: a comment on the commentaries. Health Economics, Policy and Law, 2016, 11, 445-447.	1.8	0
45	Authorsâ€™ Reply to Angelis and Kanavos: â€œDoes MCDA Trump CEA?â€ Applied Health Economics and Health Policy, 2019, 17, 125-125.	2.1	0
46	Organising Research and Development for evidence-informed health care: some universal characteristics and a case study from the UK. Health Economics, Policy and Law, 2021, 16, 489-504.	1.8	0
47	Expanding HTA â€“ Correcting a Misattribution, Clarifying the Scope of HTA and CEA Comment on "Ethics in HTA: Examining the â€œNeed for Expansionâ€™". International Journal of Health Policy and Management, 2019, 8, 732-733.	0.9	0
48	Reinforcing Science and Policy, With Suggestions for Future Research; Comment on "Evidence-Informed Deliberative Processes for Health Benefit Package Design â€“ Part II: A Practical Guide". International Journal of Health Policy and Management, 2022, , .	0.9	0